Table 1.
Patient characteristics by genotypes in metastatic gastric cancer
| Features |
FcγRIIA
|
FcγRIIIA
|
FcγRIIA and IIIA
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| H/H (%), n=56 | R/R (%), n=14 | H/R (%), n=40 | P-value | V/V (%), n=19 | F/F (%), n=40 | V/F (%), n=51 | P-value | H/H or V/V, n=61 | Others, n=49 | P-value | |
| Her-2 status | 0.52 | 0.38 | 0.37 | ||||||||
| Positive | 19 (45.2) | 7 (16.7) | 16 (38.1) | 5 (11.9) | 18 (42.9) | 19 (45.2) | 21 (50.0) | 21 (50.0) | |||
| Negative | 37 (54.4) | 7 (10.3) | 24 (35.3) | 14 (20.6) | 22 (32.4) | 32 (47.1) | 40 (58.8) | 28 (41.2) | |||
| Age (years, median 52) | 0.52 | 0.97 | 0.38 | ||||||||
| <52 | 23 (45.1) | 7 (13.7) | 21 (41.2) | 9 (17.6) | 19 (37.3) | 23 (45.1) | 26 (51.0) | 25 (49.0) | |||
| ≥52 | 33 (55.9) | 7 (11.9) | 19 (32.2) | 10 (16.9) | 21 (35.6) | 28 (47.5) | 35 (59.3) | 24 (40.7) | |||
| Gender | 0.08 | 0.08 | 0.56 | ||||||||
| Male | 33 (50.0) | 5 (7.6) | 28 (42.4) | 7 (10.6) | 26 (39.4) | 33 (50.0) | 35 (53.0) | 31 (47.0) | |||
| Female | 23 (52.3) | 9 (20.5) | 12 (27.3) | 12 (27.3) | 14 (31.8) | 18 (40.9) | 26 (59.1) | 18 (40.9) | |||
| ECOG score | 0.25 | 0.08 | |||||||||
| 0 | 42 (48.3) | 10 (11.5) | 35 (40.2) | 15 (17.2) | 36 (41.4) | 36 (41.4) | 47 (54.0) | 40 (46.0) | 0.56 | ||
| 1 | 14 (60.9) | 4 (17.4) | 5 (21.7) | 4 (17.4) | 4 (17.4) | 15 (65.2) | 14 (60.9) | 9 (39.1) | |||
| Gastrectomy | 0.47 | 0.27 | 0.99 | ||||||||
| Yes | 43 (51.8) | 12 (14.5) | 28 (33.7) | 12 (14.5) | 33 (39.8) | 38 (45.8) | 46 (55.4) | 37 (44.6) | |||
| No | 13 (48.1) | 2 (7.4) | 12 (44.4) | 7 (25.9) | 7 (25.9) | 13 (48.1) | 15 (55.6) | 12 (44.4) | |||
| Location of tumor | 0.87 | 0.36 | 0.81 | ||||||||
| Proximal | 14 (60.9) | 3 (13.0) | 6 (26.1) | 3 (13.0) | 9 (39.1) | 11 (47.8) | 14 (60.9) | 9 (39.1) | |||
| Middle | 16 (50.0) | 4 (12.5) | 12 (37.5) | 8 (25.0) | 10 (31.3) | 14 (43.8) | 18 (56.3) | 14 (43.8) | |||
| Distal | 23 (46.9) | 7 (14.3) | 19 (38.8) | 6 (12.2) | 21 (42.9) | 22 (44.9) | 25 (51.0) | 24 (49.0) | |||
| Others | 3 (50.0) | 0 (0.0) | 3 (50.0) | 2 (33.3) | 0 (0.0) | 4 (66.7) | 4 (66.7) | 2 (33.3) | |||
| Degree of differentiation | 0.53 | 0.16 | 0.50 | ||||||||
| Well-differentiated adenocarcinoma | 1 (33.3) | 0 (0.0) | 2 (66.71) | 0 (0.0) | 3 (100.0) | 0 (0.0) | 1 (33.3) | 2 (66.7) | |||
| Moderately differentiated adenocarcinoma | 13 (65.0) | 2 (10.0) | 5 (25.0) | 2 (10.0) | 7 (35.0) | 11 (55.0) | 13 (65.0) | 7 (35.0) | |||
| Poorly differentiated/signet ring cell carcinoma/mucinous adenocarcinoma | 42 (48.3) | 12 (13.8) | 33 (37.9) | 17 (19.5) | 30 (34.5) | 51 (46.0) | 47 (54.0) | 40 (46.0) | |||
| Lauren classification | 0.48 | 0.81 | 0.83 | ||||||||
| Intestinal type | 10 (62.5) | 0 (0.0) | 6 (37.5) | 2 (12.5) | 6 (37.5) | 8 (50.0) | 10 (62.5) | 6 (37.5) | |||
| Diffuse type | 34 (50.0) | 9 (13.2) | 25 (36.8) | 14 (20.6) | 23 (33.8) | 31 (45.6) | 37 (54.4) | 31 (45.6) | |||
| Mixed type | 12 (46.2) | 5 (19.2) | 9 (34.6) | 3 (11.5) | 11 (42.3) | 12 (46.2) | 14 (53.8) | 12 (46.2) | |||
| Smoke | 0.53 | 0.69 | 0.98 | ||||||||
| Present or previous | 20 (52.6) | 3 (7.9) | 15 (39.5) | 5 (13.2) | 15 (39.5) | 18 (47.4) | 21 (55.3) | 17 (44.7) | |||
| Never | 36 (50.0) | 11 (15.3) | 25 (34.7) | 14 (19.4) | 25 (34.7) | 33 (45.8) | 40 (55.6) | 32 (44.4) | |||
| Drink | 0.69 | 0.51 | 0.94 | ||||||||
| Present or previous | 15 (48.4) | 3 (9.7) | 13 (41.9) | 4 (12.9) | 10 (32.3) | 17 (54.8) | 17 (54.8) | 14 (45.2) | |||
| Never | 41 (51.9) | 11 (13.9) | 27 (34.2) | 15 (19.0) | 30 (38.0) | 34 (43.0) | 44 (55.7) | 35 (44.3) | |||
| Metastasis | 0.95 | 0.86 | 0.38 | ||||||||
| Single | 26 (51.0) | 7 (13.7) | 18 (35.3) | 8 (15.7) | 18 (35.3) | 25 (49.0) | 26 (51.0) | 25 (49.0) | |||
| Multiple | 30 (50.8) | 7 (11.9) | 22 (37.3) | 11 (18.6) | 22 (37.3) | 26 (44.1) | 35 (59.3) | 24 (40.7) | |||
Abbreviation: ECOG, Eastern Cooperative Oncology Group.